NVTA - Earnings call transcript Q3 2019

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Ladies and gentlemen, thank you for standing by. And welcome to Invitae’s Third Quarter 2019 Financial Results Conference Call. [Operator Instructions]

I would now like to hand the conference over to your speaker today, Laura D'Angelo with Invitae. Thank you. ma'am. ahead, go Please

Laura D'Angelo

and our everyone. results third operator, joining earnings you us for quarter good you, Thank afternoon, for call. Thank XXXX financial

Guyer, our today CFO; our COO; Chief us are George, Stueland, CEO; Joining Officer. Sean and Katherine Bob Lee CMO, Shelly Nussbaum, Commercial Bendekgey, our our our

call, to and results to as as encourage metrics have includes our you listen we which financial As press on our quarter. the commentary today's conference you release available, well

products, various our and remarks like call the our provisions in investment within I'd forward-looking opportunities, to product and and the focus that our the for business demand our meaning the on market constitute the Harbor not Litigation thereof, remind infrastructure of acquire, begin, of operating prospects, our we we this of businesses and strategy, that pipeline, reimbursement you plans of that statements historical Private Before Act. make including and future results, Securities operations, on we future integrate Reform are services, to and timing manage our those our our plans about services, financial Safe and

to for and our from our results predict is therefore materially accurately our could services differ It actual guidance. difficult demand

XX, as section hereof. titled These from you cause company refer expectations. other to additional to do not our the business Factors our the could materially only Our for actual performance conclude on assumes guidance We statements in XXXX, differ that speak things XX-Q date on forward-looking additional to particular quarter Risk any for information results factors legal current or acquisitions, future among that June ended settlements. we investments, the restructurings

development to these Generally Principles per loss prepared expense, available non-GAAP encourage net States you To release. expense, burn. non-GAAP operating and in the reconciliations, statements and the net general review provide we accordance financial are United supplement non-GAAP administrative and in cash non-GAAP press Accepted research We our expense, Accounting with or GAAP, and in which consolidated loss

With that, I will turn Sean. the over to call

Sean George

Laura. you, Thank

ago, to everyone years into in started Invitae mainstream modernized genetic economies. use for get we incorporated information XX around the world medical

years on XXth this for to quarter-over-quarter genetics we model with And double-digit new the of as U.S. growth underway. of personalized a we our quarter diagnosed we in all the genetic than those indication serves affecting per into many go, medicine impactful a the people have year average as X.X beyond move million believe serve. industry more industry trajectory, of the we cancer While transformation equally disorders of new is the an

state-of-the-art we every healthy pregnancies the and in genetics, the the drive genetics new million U.S. mom for year and As system at the of utilized adoption immense level. lead the in way fully proactive into we to but potentially as X opportunity benefit baby

as position Jungla Of are integrated Invitae patients We and genetic company only clinicians life. the in with quarter, capabilities of with information investing cutting edge the anybody to to whose testing interpretation us variants unknown allowing on of interpretation of of the else. most put at the significance, addition compared capabilities provide to acquired from all currently stages a lowering reporting reporting to partner throughout third costs, and and broad certainty and Invitae in the note, to time us for to benefit

will pregnancies XX clinical genome with this ever, modern systems of diagnose XX drive development allows level down across continuum million that integration trials. costs healthcare them support have network adoption million added with help the technology combined to and healthy therapies benefit and to more to worldwide. baby our our programs. ever, a to partnership The the than than path teams to Bio, partners in nine We and healthcare to patients XX to a growing We creating partnerships introduce for nearly completed the of faster Singular growing us appropriate network mom of the to treatments,

quite For to rare, it a faster Vermont the Also, simply, them program routine Network was clinical DNA genetic-based announced our with offer diseases. often biopharma a Vermonters of University for this it of enroll as forward allows part partners, of thousands trials important care. genomic future and sales testing to morning their to pull the Health

deliver we around of sign an While as the individual a a systems globe the partner feel important and small first that look benefit of manage information health at to scale. for come to step, is genetic things information for the this population

that rapid commercial million and health companies recent of landscape In covered of Company, evolution for institutionalized are succession, covered and Americans. network Invitae the payers approximately feel plans lives for by We of the commercial national space. coding, selling this provider us now in an the game XX states services started for Having in the majority aggressive achieved price also We contracted advised lives become opaque matter XX When genetics network. XXX indicator Medicaid, with with network of milestone or in pricing to Invitae the has way status. leading the in important and billing vast all is doesn't added Cigna and was government newest many in we million this high that only health aggressive win. historical, the the care, to future that of the

toward grown from in years, annual guidance than dollars has short more samples in in XXX,XXX $XXX tracking XXX and to of revenue six samples In revenue. few and our a thousand XXXX million XXXX Invitae hundred

investment with for pace to focus strategy, the outcome now, the and While year. is years our broad course, of commercial of operating the capabilities consistent remainder the functions long-term our to that out deliver it in was determined our ago,

that enable stages scale, continue information moat make needed to Invitae across competitive ever in access and deepen we we life. than all technologies to our easier As it invest widen we in now as genetic

the to our turn highlight now to quarter. I’ll over the for results call Shelly financial

Shelly Guyer

Thank you, Sean.

third our a is velocity that over business. this quarter, key we quarter volume growth increase samples, noted the we more accessioning Again, XX% a year. metric strong of have have seen of we by last the time, judge than this XXX,XXX the growth which some For quarter of

While our markets, in our the slower than our which sequential we all increases higher our third and a achieved in the growth across especially testing year's quarters, volume quarter, again growth. general, from Detect NIPS growth is experienced from normally in growth volume accounted XX% test over strong led programs. X% testing, XX% total we of pickup volume including accession Notably, for segments, one we last the sequential by of second saw and pharma our international quarter reproductive

made between accessioned and the calls, We relationship reported billable comments about billable volume volumes. of prior have approximately XXX,XXX. In we

and we there is between call. was suggested earnings in quarter, X% our last with experience the billable in what This our and a accessioned difference volumes, in line third quarter which historical

We quarter. expect in seasonality, volumes billable the will to that be due smaller there fourth and accessioned a between gap

With force over year. several reiterate are accessioned our of XXX,XXX throughout partnering further customers. NIPS our despite we our product, sales months guidance? volumes guidance XXX,XXX we at add for how We recently expect meetings fourth Typically, samples. for programs, newly the to are timing the launched of introduced we year-to-date tracking year, strengthening in additional the And stand first due medical year. year highest of to factors, of guidance XX% nine approximately some of our the timing increase the about and due This accessions the seasonality, quarter key the annual in our to

third turning year-over-year. Now We revenue. represents the growth million in $XX.X revenue revenue in a to generated in quarter, XX% which quarterly

and third-party of quarter, over revenue XX% with partners payers including institutions both from pay. our As just patient came XX% from last under and

is third-party contracts cancer third-party and tests to these Medicare commercial from to as test collect from tests better percentage on payments The get continued group. payers higher largely more payments on into high a payers payers continue due we and from more as each our

testing Consistent last goal decrease with The and quarter, ASP payer in in $XXX ASP more quarter we year's and the product of changes. was expressed from to an this primarily discussion third realized bringing of quarter mix last second $XXX to patients, our quarter. down and attributable $XXX trends our of

introduction billable testing revenue uptake more trend a NIPS contributed While patient expected third-party this pays test our more in was pharma of quarter, patients This and made have to of in to of efforts decrease was our and both the from line, ASPs. which institutions third-party XX% there part the to of increases the than volumes our program, up access which payers and enabled due testing of of billable Detect product lower volume. carry difference. Strong again X% both both

$X.X additional due in to cash recognition revenue Movement We compared million to $X.X quarter estimate the the ASP had of our collections increase picked excess also benefit due during an is in second third quarter, in to in from how up the we our guidelines. change quarter. on million much

the product Taking these standards, any that more as the lower into time. near-term that gain in under changes. history payer around will quarter but we a in we magnitude benefits the mix of ASPs XXX As bounce expect see that with will will future believe bit, trend decrease we the our we ASPs account, changes our and

As tests be in and these small third-party quarterly growing, areas businesses. our that payers, but pay expect contract international ASPs, more we increases we collect into continue offset are lower will to by get like and in pricing from patient more

near our ASPs that will pressure product changing on We also mix expect our downward the put in term.

are we summary, our annual on with in guidance. revenue So, track

our XX% of our full the revenue. historical revenue from with seasonality $XXX experience, due a both volumes million and guidance. in over Our our We collections in reiterate to strong year year-to-date of is we billable quarter fourth revenue over Consistent expect payers. guidance annual underlying

lower quarter. mix quarter, which The in In in exomes, costs Recall are quarter more time. per per did stock-based to this expensive, more volumes average and NIPS the sample specific bringing included $XXX, expected sample out $XXX the expense processing test third our second COGS The that for savings, COGS. annual decrease reduced upward an down with per have an we XXXX, yet compensation which XXXX. their changes, are of pressure the of we retention merit-based second and grants, RSU not to comp $XX quarter of on and cost approximately relatively given COGS not including are put and sample product from

per amortization related costs acquired. to We of to $X uptick intangible due developed Jungla's about also sample had technology an

impact dollar sample asset, the life volumes We will the increase. as this amortize continue intangible decrease to will per XX-year over but of

Just a comments my reminder, COGS. past on

COGS to technologies will bring expect new products fluctuate on continue line. introduce as and new we We

depending new a and products, Importantly, continue early lower year will upon on pressure to newly margins made investment products and we to and of those to a We COGS. commitment acquired have target uptake XXXX make margins. our Invitaeize XX% intend the of introduced put we and on, products technologies could gross

quarter third million the XX% We improved by year, quarter third XXXX. generating from the $XX.X in XXXX of profit versus previous of $XX.X gross the million in

quarter, the the XX% down quarter-over-quarter XXXX and cost gross quarter, sample. XX% margin in quarter decrease of per average decrease XX%, third ASPs our outweighs in the the This was from of as the last

We expect with gross will will goal. XX% trend towards our fluctuate that coming margin quarters the and

are the we growth several in enabling As and which us areas of to scale out. And and we across year discussed acquisitions, impact need operating teased stages investing last offer of two be beyond, products foster expenses this additional to life. our have and completed both quarter, business all of to

incurred million, $XX the XXXX. which includes the of operating for cost For approximately expense, $XXX.X of quarter, million revenue of quarter we third to compared GAAP

and in includes sales million and $XX.X administrative million million This in $XX.X quarter’s expense general operating costs in $XX and and marketing research costs. development,

expense recent important $XX.X compensation spend But, related understand post acquisitions. stock-based is for of business, million is compensation operating more the two whether and expense indicative the of eliminating to our non-GAAP it to base

key employees of of part RSUs million So, million, were Singular the OpEx the Bio development $XX.X to in drivers quarter? stock-based for what and granted the acquisition. research are including compensation costs First, this $XX inducement as

expansion, on spend increased the compared our due headcount and continued by content business customer investment the primarily expansion $X.X of base to reducing the business, COGS. improving on scaling Our in focused to second experience XXXX, including quarter million R&D,

includes which in launched advertising million June to Second, channel sales campaign, in costs branding million, and this our direct $X.X year. marketing costs and were of $XX.X related

General million Third, Jungla fairly million administrative from for and quarter. acquisition and costs of the $XX.X $X.X prior the flat the third costs incurred in over quarter. in were We

see related management includes compensation $X.X continue during incentive to quarter Finally, to plan, quarters. the we’ll stock-based million which in future the

and cash move $XXX.X our quarter-end to let's cash marketable restricted cash, At position. our Now, equivalents, million. totaled securities cash

During million net ATM the the proceeds our from in net debt quarter, offering. $XXX.X in and we raised proceeds million $XX.X convertible from

million we debt, XXXX interest cash to quarter Jungla $XX.X quarter million third about measure, the This quarter overland and payment million extinguish cash of these absence talked million a the interest includes in to the Cash connection in year, totaled the of of the burn, third our basis On totaled outflows, $XX.X the payment a which includes of accrued a non apples acquisition an how of quarterly $XXX apples over have million on GAAP $X.X XXXX. and burn an have in $XX.X XXXX. payment. past burn on the third would cash with

increase On the our call, we would business in year second XXXX, year. into the quarterly and that quarter throughout indicated throughout invest continue burn we the that would to our and

XXXX. we For up burning year, compared stated that in when anticipated to the more XXXX to we XX%

Our as burn could be as million XXXX. in high $XXX

overland the cash of acquisition-related have and [ph] Excluding $XXX we payments, the burned year-to-date. million impact

to the Bob. call turn now I will over

Bob Nussbaum

Thank you, Shelly.

the practice evidence-based genetics. committed we're improving of to Invitae, and advancing science At

what This limbo. genetic so advanced of undergo and instead help Many informative genetic an in frustrating positive because in VUS, substantially enhance technology means. important modeling As uncertain a Sean patient negative Jungla is is a the a our of the interpretation, leaves it to interpretation we but mentioned, people and scalable get powerful can Invitae’s is variant a not testing nor yet result, them do will significance more change there and is patients. addition provider deliver they we acquisition to receive both that VUSs results capabilities. a gene, meaning to to variant it Jungla’s or know a neither variant

also were In testing addition for we in underutilized diagnosis which acquisition, improve Invitae’s can launching programs Detect but Jungla conditions busy five the and to is treatment.

that play improve showing in information Detect seeing biopharma to board biopharma interest care. patients role partners genetic resources with programs, clinical on bringing are we Importantly, coming and together the can and our demonstrating important

a to publish American research, the research presented of clinical and demonstrating wide for and at Human the Counselors. National number expanding medically those as health. to we the continuing Society we're such, their how benefit critical to to also from from genetic expand. testing. people and Society open Of actionable note, to for access studies, Genetic genetic It guidelines of up mission that their benefit can it all We Invitae’s is that information range of understanding And testing can Genetics, highlighted continue continue access seeing to impacts

Invitae on to Network clinical program that partnership pleased routine with as the Vermont. people announced proactive part University Health screening genetic of We're care for of their testing Vermont in us our offer the

public we the into actionable health. within system, needed be as This providers healthcare embedded and testing genetic We the University population-wide information will further people such The in their have continue conditions ample are of to manage on impact condition evidence to care of. genetic that so of a one also patients grow Such medically large program to that for health. genetic they testing six demonstrates will genetics the aware Vermont a actionable testing program have a evaluate scale. medically into of actionable and medical integration of have the genetic not future testing project

over I'll to call turn now Sean. the

Sean George

you, Thank Bob.

our profile us, is We strong unbound sheet, growth potential to leading the transformation balance in generics investment and ahead on industry have we track see a years the to come. of essentially

advanced driving also that point been feel which the the around at historical technology an of a and individuals starts diagnostic pace adoption delivering to are We a to of of globe years genetics we that approaching we've the many in for value industries. in industry, accelerated bit ever-increasing one relative to counting the transition surrounding

in volume growth the ultimately operating clinicians cash drive increasingly the and of The the remains on genomic gross and on our indicator best flow, and model to focus business, our future. be network the genome success testing all growth serve. focused that into our translates metrics the absolute the will future our which management information that rationalizing remain financial benefit profit of patients expanding We we top-line and are the forward in moving of business

the With I’ll Q&A. turn operator to call for that, over

Operator

from from Cowen. Your Doug first of comes line question Instructions] the Schenkel [Operator

Doug Schenkel

and taking Hey. to target bit. Good come a little the want my start just guidance you afternoon, more near-term, a back breakdown financial question, guys. Thank with for XXXX to then long-term trying I questions. to

back, So tests A processing XXXX $XXX. X years couple starting of at on of financial the targets. and you at an ASP financial million long-term targets set

the to lot or two credit with be that the would the current imply target, take keeping XXXX months mind So, thoughts prior the with love on side right for a to doesn't So, forecast in getting revenue from whether we comfortable can that willing below I to valuation all you next those what do With well as the as sit year. stock And you target. of about in would for math consensus we Thank in way revenue to on that to that go that the comment year? sits you're XXXX would the next would mind, we here with to you. XXXX? two think target well on I in street year, XXXX is not your that. what's argue And your revenue go below consensus Current months get here in you sit are consensus sell targets.

Sean George

Doug. appreciate Thanks, Yes, question. happy the to. I

truth a think as question. know which that or in out, investments numbers large front X-month will windows I you as next I play stating mean, that the it ago a X in windows do but as result is, out, to know, to of And play predict, part worth made think, not not but longer. I the -- year's -- it's of two I as always of the years easy of course, dodge,

finalizing still are for commercial XXXX. our investment we plan said, that with operating Now and

giving to practice of stick January. guidance we'll the So, in

do say get numbers were couple XXXX in for a is, we question. the XXXX guidance over would a as mean, And will this premature aspirational as which what models to again, change context, now, anybody X to that would the provided street in laid the be think back, ago. I it numbers, we I until we step January. far million And their years I for I taking talking year, fair samples $XXX about of those million, think, are As

there whether investment real it the justify growth huge, technology. TAM that was of the in suggested that We lie When was not indeed years is -- and question to the we're or the time, high as value dialogue many no the few this, ever trajectory company. building conviction At believe ahead. on, the people as in of solid else very on and is one currently this that in we're a a the

think, I direct understand but on at I sheds So, on answer, this hoping a our the it not time. I'm position light that

Doug Schenkel

That's for way to going way. on but to object say synopsis? okay, that things Would there's off but street’s go on Sean the your mark. in a somebody modeling possible, suggest And helpful, to few that next a the that Is business different In said for belabor is based in what financial a this, to said, just saying, still just you Sean. year not maybe what happen. you meantime, target’s to fair nothing would the the going what XXXX

Sean George

That's like to impetus say it. right. this time, there -- update advise, said, no would I'd models if were, say at we I'd there's I

now our a something guidance is are to have rapidly business, As are -- is our practice, achievable. as growing that to to such, we the know be very always business very want but and drive continue we large

good summary And absolutely as as any. -- is that think, within your so, I context, I

Doug Schenkel

Thank That's Okay. you. helpful.

So, of a trends end. about we into questions couple your think as heading

I'm in I I full than you productivity believe of messing to get of full-year what I better. the to was, I'm curious that but was new QX year your fourth this XX how comes not in to the up. about So, it guidance, when force I revenue quarter, Hopefully, to To $XXX,XXX extent, last need doing think, by $XXX,XXX, quarter, in And to increased context some guidance? since guess, view But better of little quick around to per not beginning year. this the much math. rep through seeing the of rep hires. per bit your you're year. be a with some just So, headcount you've sales per QX

QX on me makes So, ability hand, your that to pretty get one feel about numbers. to good

what hand, on ramping other the because think, XX% actually the a to that improve to new is fact the than relative would little you're last productivity On using by same I about productivity lower you it think, did XX%, was based QX, people, I to metric, in need the year. just

hoping guidance? seeing you XXXX are can can out comes getting just that about make it feel when So productivity us you what to better to us I'm help you

Sean George

Yes.

we think the the that's expect been question. has fair mean, year. same I to we have this strongest quarter, lot, been So, by I obviously, Look, a traditionally QX oftentimes like for and would day, that doubt than to guidance. mark, -- approach to comments at that, per end closer how or the annual we no my like as of guide this QX about of are, at previous we

With increase bit profile productivity a than that like. if get point QX past you you same that it's you like, right same made tiny to a the year’s higher volume is higher to there. look what -- the needs the in year, and to out what rep It's QX much at bit to in the The how than one. growth statement little line, the not consider way look needs revenue said, as profile remains that

in the additional got we this said, August that motivated. of had finished so, really run the of down year. team and adds, this To whole, second year, team contributors. of the the highly The And to full they sales to year. with productivity that That really continues kind end some entire quarter be

things a are we we year's last an effect when our addition, handful timing that effect, pharma launch account was to if consider expect did is of also, that the the additional weighted different And up NIPS as we've And those, of that back you of contributing the aside, program, pick pace contributor, spring, of launched toward we've those end are an the up. the and of is year. we the back end all own. something in pharma feel the continue And year also programs then end picked knew be that year. there course, seeing see that will we and would are we next The indeed be a the from of

go ability -- think a where like that had said, our And ago. it's taking of the remaining and general two that et acquired, So, run commercial again, But, Bio We've give think -- these this when in tracking. our seeing now the profile statement was technologies yes, developed run especially new of the that to think we've the consider even it incoming moment kind what now, recent I what example, past, this of momentum year the we and and similar And, I the hands and we -- where team Singular that we we've operating past. we hit like really as the is year, our -- of cetera. we've next to back, business, a confidence out operating a as commercial remaining been the Jungla, ability, when These, and and/or out. the for about as of investments quarter. are where looks it is months we're game like, the remainder step it's back, you you and I three the made years teams in that cannot again, us contribute over show also two step things the in take got we they we're if a now

Doug Schenkel

more That's And recent great. the topic, I tackle front. coding Okay. developments if just just on one some could

one due first, Doesn't business. their and I'm NGS something sure what changes code. and impact attributed materially not reason was as specific coding that newer any So, was just your completely the want sure the aware, to materially multi-year make that Myriad on that to of I peers whatever for that CPT had the year your would they quarterly largely business. results cut seem your move something like impact with to missed full being space as you're guidance in Myriad, to

new that use And to is, I'm for seems actually was germline on NGS by then, an the curious think ovarian second It that FDA based exists. in coding question your cancer. thoughts NCD I approval test the require CMS. what just are proposed don't related NGS breast and of

happens you do practically approval? think So speaking, does hold this and here? what extent I FDA to are that your to and efforts up, you guess, the where pursuant

Sean George

Yes. answer tone short coding. really future noise of and feel I on because all of impact that confusion answer quickly has business. The none as the is there will any is, of our things we

Lee with for flavor Now questions said, give that and it. more through both you detail more in some walk those can

Lee Bendekgey

Hi, Doug.

question with has So, the do first and to changes coding private payers.

though, it coding understand codes. this pricing contracting is At retired I problem. revisions the As with true And BRCAX a retirement the that is this and do is coding those a has of has BRCAX its heart and not to that year issue codes. raised been problem. couple that of the old This a earlier to manual

down. for as have payers It we with private contract longer We than it that our that of contributor ago, said likely correct but is many negotiations and made prices would've years us come because is years presence done imagined felt And yet. any say now in taken us to not it has few to you probably we're are affect doesn't it a it. happening would the that major

impact third on -- question I of about our that’s your think party contracting answers So, the prices. that

to decision. coverage the regard recent national draft With

advocacy we part was concern some and the was a among from was that cancer late of folks revised stage wrong testing time, the to recall, there expressed of an we CMS. months suggesting So, you’ll indeed, no to and expected, And, longer industry turn. the societies, of was a not that limited stage coverage version this into being professional apply but national resulted cancer the uniform go the there sort the on coverage groups patients. ago, germline the widespread that decision the as reaction that And all this, only that at misunderstandings for was that earlier patients. as at of history late And is reflects national labyrinthine decision the to view of interpreted

have We, language available new are breast aware to would reimbursement would piece believe seems we tests that the as such non-covered. intended be or HBOC for you, testing approved. were We FDA all essentially tests. do there any available you be only cancer -- tests CMS if syndrome minute of not And anomalous that's really for render for that and hereditary not NGS in germline only that for said, a to cleared a of germline suggest ovarian what like

will point, that be is what either somewhat meant a FDA bunch a people. we with approval. based was would conversations loose or And a expect This on that reaction they of of that it's that just as companion a possible similar preliminary had diagnostics of on use need so, sort there we've universal language,

sequencing devices since that Now, FDA. Those was they had the to been in NCD that are there But, also think essentially I they PCR. based our generation which original companion know by test. be in the have approved, one also is any on what are knowledge, are foundation next all mind companion that the case, approved test, may a

resolve worried the But, minute be they or outcome don't I may the that's intended is that a for are that will about think what NCD finalized. it mind. in CMS what people So, that had what is when

Operator

from comes question Morgan. Peterson of Tycho from JP next Your the line

line open. is Your

Unidentified Analyst

for Thanks. Tycho. is Hi. on This Julia

outwork? network and embedded moving impact any and Cigna. ramp think the with give of you Vermont color volume progresses in two in the the about from those So, on How more on sort your Are of maybe, those contributions should the could us ASP? XQ we partnership

Sean George

Yes. I’ll go there.

for one, that happened. much isn't I know say volume. something it we've paid. that Let's -- And working a get one I definitely an That's impacted isn't start Cigna. don't would many on while. That been -- how how impact roughly, And It's we -- that yes. much a just as with so finally

contributes of third And that been past that yet over more Our line. improvement has insurance one be steadily this reimbursement will to many that third party quarters. reimbursement the thing improving party steady

that's pockets of answer little But, finally past quarters. and necessarily in volume it which for you're revenue questions a with whatnot most se. is in bit easier always of about for clinicians gets increase consistent impact, not part, the So, out once little There's contract. per a game, a to network and when few

apologies. had flying NSGC. to Dr. off. to and He's Vermont, run Nussbaum out On

that. I this category on him the is, in our preventive would genetics. But, is answer for proactive more So, bottom-line this or Vermont to assessing have loved about

not are We in our at really line much all. forecasting this business

the of So, in the largest this that serve use think proactive, it’s mainstream in reproductive market, healthcare developing one, diagnostics, we a we is newly it when we this something of is, three systems. feel proactive genetics -- is the one large is everybody health and that where medicine

the super excited all for in with super about it, implications working do So, to the this, excited right. of kinds it future There are model. about this system do to future

With that will time. things said, take these kind of

operating anticipate an six clients, be don't over for I will be we're as quarter tops. for rest going think dozens jump the a -- a like so, it thinking the rest on This where over the It's of it'll these of the clients a in I'm huge volume any to look of as will making been result time. of recognized just business lot sequencing revenues things. of on example, at years. of volumes population type to any not phase of a And time. add or has we and result business our for single in frankly point given or like distinguish Maybe volume, from, are to goes business, up programs we I a these of past single one our add come,

Shelly Guyer

they quarter that that quarter it quarter. the to thing I Julia, as will I they whether were much that actually expect fourth were collections fourth since going come of and lower It’s out in what be first have will us pop able a see be that in see to revenue recognize we fourth recognition Xst rates know, add the But, account that we the other be the on don't And to those to see under the quarter. will in for contract, the effective up. have the we would when you know pay will criteria, the date, those just able in Cigna, is and December we'll one whether up. Cigna question we effect or pricing would whether

Unidentified Analyst

a appreciate side. ran That’s pharma of on it. the the your moving maybe a network going of should pace certainly to given helpful. and that pieces dilutive effect NIPS quarter-to-quarter, time, help mean Cigna just are partners, very near there with is fluctuations in on Got could in there. But, lead positive mean, lot the in we there And then, margins. I from term the certainly that

that -- expect for as gross I how sort that So, But, guidance, term of could about we from do a you your in trajectory? we the we think mean, towards moving to maybe necessarily are sort next asking chances a trend get but mentioned there you we lower think general you of without look go goal. near levels the any term? should near be current XX% year, towards margin

Shelly Guyer

X% quarter Jungla the I'll And would note had that answer based Shelly. that. I diminishment amortization the the It's a intangibles. of this XX% on

$X continue will X%. that. Those to about feel per we and so, per And COGS was that sample

it So, not patient but the we but would margin, will in by in as get third you areas, XX% that payers, institutions, higher such badly is but mix some is, expect and international ASPs been because I -- lower as of be prior from which the from some offset would of product know, have pay. prices quarter. the the party areas change. the that the down slightly gross And that down would

switch more next see may and would higher begin and Detect some programs to downward collect to as with the in floating I time, that perhaps year ASPs this expect we other So, but as of the some that year. continue that of things we’ll yield that rate, that

and always move So, said, it, up collection will a XX%. of the trend just to around And also it we've side on back not as side. be will bit COGS the depending fluctuating, it will it

trying interpretation, such automation the as and will all capabilities things So, reading that medical down will drive on acquisition as COGS, down. COGS work that such to we to Jungla things continue variants, bring our actively and some the of

several I driven next stay So, that ASPs quarters. may are, the over down where will COGS the but the they similar would expect be

in over some time, near but So, term, fluctuating. still the improvement it's

Lee Bendekgey

and want The going or XX%, we think I have Lee. the we margin our reductions. to add I said when this continuing Shelly focus for right three year. on the we made quarters thing -- for content -- -- I that's delivering what COGS two we we new what on to was doing and couple around having last adding COGS were than really only would much quarters, a near-term, is been we of to But approached that model. we were on in are probably reducing this that ago were more work This And content is of the expect to point

so it bit reasons also one is little on it is, of see much is -- vary And a launched. content being you the new that how from quarter-to-quarter, why might based

Unidentified Analyst

How from versus, compared it. expectations? Got volume how us then does testing you those about carrier tested patient could just how very initiated depth significant And the Thanks. of channel? diagnostics the was And mix testing versus was date? an screening was I the to sort me. launched. And the lastly update -- to on since That's of helpful. if generated sales for the sort proactive contribution versus wondering give it

Katherine Stueland

and it's would going off well direct Katherine. about we as ASCO of this at kicked channel this year have offering far, So, We is our the expected. thus in June, as

overall this time over contribution to to We that's grow. expected we numbers year. the And for going volume expect minimal

key really As for about of that of been areas And a doing to learning it, of in capturing I through be us the mindshare is growth a the of going gatekeeper of the kind think, we lot marketing. we've with think work initial we're really health. as digital terms one women

to terms of focus be So, beyond moving offerings carrier our forward in a us that. cancer for that's and going big and

I been though across interesting menu. seen think, to really is testing that what's ordering from see we've our

built And of that past six able one that in We've to so, driving a in terms strong medical us the our interest years, to going that's think I their being to to volume also channel. lot utilize help addition succeed the we've and clinicians differentiators brand of patients. of channel that with the from through is big over seen

it's the I'd going channel. successful years. growth do that But, the be say all level terms several to of companies be of in So, been to for anticipate going next a of don't in think a really that to consumer-based we spending over marketing. that all, is driver we're introduction us important We this

Operator

Leerink. question comes SVB Your Souda Puneet line from the next from of

open. Your line is

Puneet Souda

keeping just you maybe increase at wrong. XX%. number And But, sort sort -- the I'm imply if past. Sean, significant I reported in And understand have and XX% of where help looking intact growing. that maybe but productivity other of here. Shelly volume, quarter the addition is share? force growth and here, about and to in competitors the me is Correct I'm Hi. in double-digit first the now sequential My potentially confidence market get accession Thanks, that, you're a what ramp to here. that do is But, you've your Is does the terms added And Is on volume. like year appreciate I and for a just delivered a test Lee. that guide question me delivered what appreciate it guide. seems terms high-teens mid-teens sales you and mostly is the IPS fourth get and -- it? the in is it of volume have One doing mostly you strong NIPS? of to segment in what their of hoping you're they're

guidance an accession here gives trying getting understand just sort the I'm near-term to full year confidence the you or in So, volume? to what of

Sean George

Sure. question. Yes. I the appreciate

strong much a needs by always years, the year QX historically the been little XX%, versus it's XX% The Those to more but volume year in XX%, -- look been in you -- it not in quarter-over-quarter growth sequential high-XXs. or in quarter, quarter. past has versus strong not it's prior years last a more. at has can it's numbers, lot but So, a it can that remaining very at there's rates. whether I would a sequential the year, and while QX, growth yes, you the a -- rest -- of revenue, say the be look And

-- we I previous there's a on big and QX a think acknowledge we to I QX. expect mentioned have like big so, a And we're question, that ahead

in now the productive. of reasons in came August, the And focused highly fully adds, end the three are, and ramped are team sales now on motivated, The major up whole we force added only year. and the is

Our our is penetration take, volume NIPS account and account increasing segment. OB driving in the

said, With mentioned We that year-over-year. for that immediately turn would years had another Yes, off I've to many [ph] into growth never competitor. XX zero. XX% out, as You pointed XX% expect confidence counsel -- also to screening there's and/or space the in of to million the X that both. extended year, is prenatal every of pregnancies million X get carrier carrier non-invasive that screening or reproductive or X million the only U.S. on

business and former the counsel, we smallish plenty the counsel as Progenity to grow there's still as businesses. that So, Natera, feel in the room of reproductive. to perform continued pretty lab And core well well,

do the a And we accelerated contribute it handful pharma year, middle year out move then, -- and the this and of we into even next. that and the third that we mentioned again volume we of off strong of close kicked as pace strong expect which programs, towards

contributors weighted. the of relatively our view three the are backend those -- So,

of As I six, love be the guidance. we'd more hand to yes, With execute seven annual comfortable did hit the perch to our we our next teams said, and next commercial a in are tracking before, that the in operating mention presently weeks. it's

Puneet Souda

up trying reduction start volume? overall, could that I pharmacy’s on to are touch of how NIPS cost take of for tracking your Singular understand Bio and and from And Bio expectations here. when just the significant if Singular And benefiting I'm ramp you to NIPS versus sort do some you

Sean George

XX U.S. production. to XX acquired the track And to generating pregnancies year, is it pregnancies there start a we ton on the of percent We XX XX in margin, the that’s play, modernized only to million afford million served begin at that that. That's cost healthcare a again, months out incorporating again, a way a systems, the expected at eventually it's the when globally, volume be only an plus into of by prices we begin it's to bringing which technology our not so volume, feel down. think every target X opportunity gross still to much kind more kind that. Bio And, are can million pointing view, NIPS. XX served So, Singular to immediately the And of of, in our importantly, we play. X which for to will really company, cost

the teams we're teams -- are we still are anticipated, mentioned, and timeline get So, is development had like the as that's integrated, now. excited And the I go. to that working

I better think, young a talent, better and we're done we're love injection relatively getting acquisitions, getting at of to they far, effort. of joining great -- we've get even so new focus, the a handful for dedicated integrating company, teams small them. larger It's

So, things are going well there.

Shelly Guyer

Singular down. On COGS, to able technology. in bring that is step bringing an add getting drive we be we with that stat interim the the house between And goods cost just down and will here Puneet, to and it is be the our of there I as that COGS a technology into will Invitaeize step and to would be Bio,

stand we’ll we'll it currently move Singular. So then that out, to in and house bring then

that's singular acquired So our that plan. we and was still when currently plan the

Puneet Souda

of term sort on expectation in bearing Detect the it charge And and if me the volume? cost of Okay. still you. program testing of Thank genetic what's full you longer -- can the are no remind you and programs, is in here that, terms

Sean George

Yes.

in we those we for vary So, of them a knowing or other partner however, We detect full the ahead only kind we've some who analysis. different -- couple were. for or years, the payments programs hand pulling are the identifying we did up, with contacting and/or Detect either basis as than in in lined is per And out no them, whether in and on cash for people of five program. Whereas data or of it well, o interested Detect barrelhead done go that time programs. are patients are pharma that's dramatically -- The sample pretty our patients. past paying to similar the programs in on

said, It's individuals with physicians, the Our is great a enough win, point patients more are more for experience pace. it's and, win feeling obvious, like we The everybody. for -- And of economics there, better. they're us. it's diagnose win, these this at rapid

For the And us, then know, at our clinical pharma pulling and shortening all your expansion of you for forward essentially were it’s -- as peak here which partners, trials pulling market, forward Invitae. sales. we’re about

but we said, contribute those that ask testing -- yes, volume to when we lines, are yes, in outsized out pharma how as play other the do well programs think of yes, to the compared the will the And contribution, we will but of come. years about other you that specifically, that by So, -- haven't along. think broken optimistic way growth we some

Shelly Guyer

going. the a would answer in programs of to in there where future. the and that we is important we It those the is questions see And margin one have about this, gross Yes. then, that would higher payments prior expect we lag for

So, and at we partners. then are able find to patients onto get those those program later point, our corporate this to

that and more. of enable programs will some or to now, to where you next getting pace programs so, those each And sufficient amount three we're lower those of then a cover to one, you, pay as see get those year will reverse two, in you partners four you

that So, time. takes just little a

Operator

Your next from question DeGeeter comes of line Kevin Oppenheimer. the from

is open. Your line

Kevin DeGeeter

the the have tools unknown testing of of and component little question. you manual you're kind unknown RNA-based of and kind role Thanks. been reduce thoughts doing. those the discussion there's a my to topic kind Hey. technology specifically of -- more for about Can on right recently calls just kind just you call Do of you of Thanks of the now of variants a, general the and bit configuration feel your work variants kind of assessing taking significance, of talk for some significance?

Sean George

we question. we believe particularly cutting The Thanks. are variant the resolution. answer that yes, to short interpretation, fast of the absolutely when comes it on That's is, fun edge

allowed more classifiers clarify with and patient bus now and impact, we far argue already valuable molecular things had we buses incorporated reduced individuals, would improvement our XX% with a for our is portfolio really the wild areas. mentioned pilot that -- acquired, as program some them, important for us basis Our That's we a our customers. we predictors variety across some impacted of on than the have rate analysis to Jungla. an in percentage a some recall by in RNA effect AI disease That's

And buses offer and nonetheless, can RNA top like for of of But in resolve we yes, that's on help some the variants also customers sub that, all cases. sites customers. percentage it about supply the which we the analysis are

And interpretation pipeline is are bus suite our our well, so, ability of and our we offer now core to variant that world-class as of a resolve but kind think we taking both entire specifically step,

Kevin DeGeeter

just then, more me. one And for

did NIPS to in call times the You contribution quarter. regard couple a of the impact out with of

of of that business, of Would from currently? As impact out and my we questions. it volume maybe session, fourth in a kind for an grows care comment kind you take as baseline to size contribution think we can different potential quarter about the Thanks this So of perspective. to question ITS on taking the magnitude the into XXXX. quarter for fourth

Sean George

Yes. pretty or steady the With reproductive the again, No, specifics And business that the out business Kevin. thanks, our for lines. has don't know break so unsatisfactory different I of business. we acquisitions, said, of our been more since XX% our less or crowd,

to has And time, that launch more bouncing growing in start but roughly. So us around rapidly. our over enabled yes, NIPS

it so, is contributing. And

able to be will accounts. up are there We pick --

calling disease a in cardio, that's that swing screening cetera. think huge carrier whether the pediatric, the say, everything way point worth as of et view -- be or I that's it at And not it's With numbers, testing said, whether other would one the exome, out cancer, be it. of the against in else, time. best this our I neuro, in backdrop it'd It's --

specifics, have reproductive we that. we're to easiest of out here can an because are not with. We -- again, to and grower the our I work that breaking be to pricing offering, point pointed the think next year our But on numbers health market the involved offering, the believe continue do share to will where we broad outsized being

Katherine Stueland

being one One comprehensive product, would is know [ph] for another benefit utilization of that add grows which then, of thing utilization product of we the to offering. having that the a clinician and I another, provide grows able

offering volume. carrier drive that So, cancer having help volume an NIPS helps drive our

products of So, the a think, within all that I various offering there's clinician office. compounding we're the of effect

Operator

Thalmann. of Your next from question line the Jeffrey Ladenburg Cohen comes from

is open. line Your

Jeffrey Cohen

I if just had may. two, I

in could of firstly, to business gaining the more So, strength are out, weaknesses specifically you about channels and any and OUS you little traction? specific talk more are you going kind call which a geographies

Sean George

again, No. to Yes. I contribution Happy OUS business. solid solid growing our mention so -- from and did

commercial tariffs raise are of fair these capital We hiring, we're landscape is know shipping amount paying but now of -- go I the the patients general broad are is, to after shipping basic point and to the us support of are then, thing. the -- wouldn't for now bizdev are the care costs commercial you as indeed where kind kind that use also, think, of help some major expansion we they logistics, of last of really really kind proceeds and will some much customer are I time service, testing. specifically of investments We've at our time where sense volume, now And to where take price trade There that. having of country begun is our modest in showing whatnot. as the in reasons in and and a a kind is almost driving that say regions address expansion, a -- We it it. now

reasons their of be history, things over clean will this focusing kind Northern and and some then, one And mostly then strongest for year. just Pacific. ex-U.S. all into the -- that particularly Latin Asia, of are without interesting, a give Middle regions two is -- on Asia were from And job The those number more course strong, of volume that's we'll of think alone regions that up. going and East a Those to go we'll is America lot there. start next us Europe, So, frankly, we the

Jeffrey Cohen

you provide Jungla expect that the would million as compensation? And [ph], the I and you from forward? had the far going quarter then, could on management you any stock some piece from the know spend as what further side, XX commentary

Sean George

Yes is -- commentary in I trajectory given Shelley of kind can I given think that offer think the can our color and the the get this So, couple how details. next we gap what of reporting gap actually divergence modeling and for and go, and is our likely the is are business this going really the important of years tracking it. further to beginning

can said, that digging with so, on And so I into start the details that.

Shelly Guyer

June was a is stock-based the and I as there So, comp key information there that million. And today will went a we million. reason the that lot up chart million. only you for also on But singular XX.X was late about that this. last about had in provided was closed is only acquisition, that indicated, Recall quarter give in more X.X the offering

only And had so, we a small proportion.

and that forward. acquisition that sort what So price, of had price. the million, you earnout was is being be moving a that was we can about proxy will use compensation $XX this it quarter’s XX.X the Remember for

gets out months, for of XX XX sort that that take So, XX that to and million. you

paying We of of success probability will we those that be well milestones will those. it's some meeting of be marking $X for it's each the them And time-based. amount market, as a as

of consider. the And so that's it chunk you to largest that need

also new. executive And did because some several higher out in management, over and continue quarters it quarter next call of we comp then, see to will the And was this that was stock-based that the you for the also.

breakdown those the queue. is of a it. in components And there So, are the key

Operator

line of of the Labs. Capital Market from one from comes question next Ophir Your Gottlieb,

Your line open. is

Ophir Gottlieb

anyway. going about my talk for possibly but next to try taking I Hey, question. want [indiscernible] to guys, thanks I’m year,

[indiscernible]. million prior billion debt at about convertible your going say for you able cash are as new raise to $XXX have that capital we’re sufficient next cash $X.X the after With continued year, the do XXth. and elimination And in of September offering the looking cash, for next not given reach to growth in debt, a of the you're

without accelerated rates gross standpoint say planned and XXXX of maintaining or hitting revenue too the far while growth through system-wide capital you. Thank there the is margin that no can we end So, XX%? going out, raises near at

Sean George

Yes.

company that to is operating -- we cash that balance that now investment realistically flow a and to for So, the the growth on. kind since one the enough investors’ cash the thesis, the on -- last the we instrument, same, needed. dynamism quarterly I the the answer our positive, the we under that in to from operated flow business -- top on aegis that are is of you think, cash as time that think of sheet pushing momentum is the will the what that on are aiming on, always quick tip lot operating if last on the is debt probably and a We've to Since return line return targets target weekly, when same. -- per we're fall, more appetite our have we reflection like first of another. on the profile the about got margin continue versus with investment, our assumed almost point And maintain gross

one the other, a way. will we're and of we've long in burn in saying, keep based we or the value And way be of in going the we to that goes the of business on all to need, extent landscape, entirely -- maybe that the where the got continue term. term creating strategy So, it an the way the capital front landscape is the executing immense are we think building of long long confident evolution right us, which is immense to market

So, that's question. next year where I that would one leave cash

Ophir Gottlieb

a such still to largest guidance disclosed if business, essentially, business? you is Do that already within positive, flow your having your term that had you a quarter, the already maintain profitable business as cancer the cash use

Sean George

I is Yes. the yes. think or could With we not take to be. we’ve point, while for in a used At short back said, hand. least as and did as say, short and I dropped would the that move that demonstrated the quarters do make would quarters. it on answer did half got really I bigger quite don't it cash x we're -- timeline this two we do would burn bigger, of that quickly. -- three we getting as is and Yes, it clearly at turn

we So, how that out. we point it to your time sort exactly sentiment this generally of in is time. that got lot But at a -- do

Operator

There call are D'Angelo, time. to you. at Laura back I further this turn questions over Ms. no the

Laura D'Angelo

joining us today. soon conferences. to for look you catching at you upcoming We Thank up forward with

Operator

this you Ladies and participating. call. for concludes Thank conference gentlemen, today’s

You may now disconnect.

Invitae (NVTAQ) 6 Nov 192019 Q3 Earnings call transcript